Lupus & antiphospholipid syndrome
Assessing the Utility of the Montreal Cognitive Assessment in Screening for Cognitive Impairment in Patients With Systemic Lupus Erythematosus
Authors' conclusion
The MoCA does not have adequate concurrent criterion validity to accurately identify CI in patients with SLE.
Study context
- Population
- Adult systemic lupus erythematosus (SLE) patients
- Participants
- 285 patients
- Comparison
- Montreal Cognitive Assessment (MoCA) vs American College of Rheumatology (ACR) neuropsychological battery for cognitive impairment
- Outcome
- Accuracy of the MoCA in identifying CI vs the ACR-NB (AUC, sensitivity/specificity)
Methodological detailsconcurrent criterion validity, discriminant function analysis
- Concurrent criterion validity
- Discriminant function analysis
Performance
As reported in the abstract
Identification of CI vs ACR-NB
| Test or model | AUC | Sensitivity (cutoff 26) | Specificity (cutoff 26) | Sensitivity (cutoff 28) | Specificity (cutoff 28) |
|---|---|---|---|---|---|
| MoCA | 0.66 | 50% | 69% | 80% | 45% |
MoCA
AUC0.66
Sensitivity (cutoff 26)50%
Specificity (cutoff 26)69%
Sensitivity (cutoff 28)80%
Specificity (cutoff 28)45%
Further findings
Added value of MoCA to Automated Neuropsychological Assessment Metrics (ANAM)
- Improvement on the AUC with addition of MoCA to ANAM
- 2.5%
Original publication
Assessing the Utility of the Montreal Cognitive Assessment in Screening for Cognitive Impairment in Patients With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). Published 17 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →